GlassScriptPhysician profile
Laura Maier
NPI 1366159394
$5,895.33
in general payments reported to CMS, 2019-2025
24 companies · $2,322 in 2025
The $2,322 reported for 2025 was more than what 94% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,682 · 2024: $1,891 · 2025: $2,322.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,895.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,895.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $886.26 | 2023-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Janssen Pharmaceuticals, INC | $704.80 | 2023-2025 | Spravato |
| Abbvie INC. | $621.43 | 2023-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $593.36 | 2023-2025 | Caplyta |
| Neurocrine Biosciences, INC. | $531.83 | 2023-2025 | Ingrezza |
| Axsome Therapeutics, INC. | $416.46 | 2023-2025 | Auvelity |
| E.R. Squibb & Sons, L.L.C. | $338.76 | 2025 | Cobenfy |
| Alkermes, INC. | $301.70 | 2023-2025 | Aristada, Lybalvi |
| Corium, LLC | $287.67 | 2023-2025 | Azstarys |
| Supernus Pharmaceuticals, INC. | $281.04 | 2023-2025 | Qelbree, Qelbree |
| Tris Pharma INC | $247.33 | 2023-2025 | Dyanavel Xr |
| Teva Pharmaceuticals USA, INC. | $186.88 | 2023-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Idorsia Pharmaceuticals US INC | $139.17 | 2023 | Quviviq |
| Lundbeck LLC | $107.61 | 2023-2025 | Rexulti, Abilify Asimtufii |
| Takeda Pharmaceuticals U.S.A., INC. | $38.38 | 2025 | Trintellix |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $37.13 | 2024 | |
| Noven Therapeutics, LLC | $35.08 | 2024 | Secuado, Xelstrym |
| Neos Therapeutics, LP | $23.41 | 2024 | Adzenys Xr-Odt |
| Tempus Ai, INC | $23.06 | 2024 | |
| Bausch Health US, LLC | $22.70 | 2023 | Aplenzin |
| Vanda Pharmaceuticals INC. | $20.74 | 2025 | Fanapt |
| Collegium Pharmaceutical, INC. | $20.45 | 2025 | Jornay Pm |
| Indivior INC. | $15.73 | 2025 | Sublocade |
| Biogen, INC. | $14.35 | 2025 | Zurzuvae |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Maier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.